Phase 1 Trial of Investigational BT-11 Begins Dosing First Volunteers, Landos Announces

Phase 1 Trial of Investigational BT-11 Begins Dosing First Volunteers, Landos Announces
A Phase 1 clinical trial testing Landos Biopharma’s investigational therapy BT-11 for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), has begun dosing healthy volunteers. Landos plans to enroll up to 70 healthy participants in the randomized, double-blind, placebo-controlled Phase 1 trial. They will be assigned to single and multiple ascending doses of BT-11, or a placebo control group, to assess the safety and tolerability of BT-11. “Launching this trial marks a significant milestone for Landos and represents the next step in confirming the safety and effectiveness of BT-11 which has the potential to greatly impact the treatment options of millions of people afflicted by IBD arou
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *